Clinically Significant Differences Between P2Y12 Inhibitor Monotherapy and Aspirin Monotherapy Have Yet to Be Demonstrated

被引：0
|
作者：
Bates, Eric R. [1 ]
机构：
[1] Cardiovasc Ctr Michigan Med, 1500 East Med Ctr Dr,2A192A, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2024年 / 83卷 / 01期
关键词：
DUAL ANTIPLATELET THERAPY; P2Y(12) INHIBITOR; SECONDARY PREVENTION; METAANALYSIS;
D O I：
10.1016/j.jacc.2023.09.833
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：e9 / e10
页数：2
相关论文
共 50 条
  • [21] P2Y12 Inhibitor Monotherapy vs. Dual Antiplatelet Therapy
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (05) : 1156 - 1156
  • [22] Aspirin-free P2Y12 inhibitor monotherapy immediately after percutaneous coronary intervention: A systematic review
    Yu, Shenglong
    Guo, Linjuan
    Guo, Huizhuang
    HELIYON, 2024, 10 (15)
  • [23] Role of Monotherapy with a P2Y12 Inhibitor for Secondary Prevention in Patients with Established Atherosclerosis
    Juan J. Rodriguez
    Luis E. Baron
    Oscar C. Munoz
    Jonathan J. Diaz
    Current Cardiology Reports, 2022, 24 : 87 - 91
  • [24] Role of Monotherapy with a P2Y12 Inhibitor for Secondary Prevention in Patients with Established Atherosclerosis
    Rodriguez, Juan J.
    Baron, Luis E.
    Munoz, Oscar C.
    Diaz, Jonathan J.
    CURRENT CARDIOLOGY REPORTS, 2022, 24 (02) : 87 - 91
  • [25] The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention
    Luo, Liman
    Fu, Menglu
    Li, Yuanyuan
    Chen, Zhihui
    Yu, Jing
    Luo, Jinlan
    Hu, Shuiqing
    Tu, Ling
    Xu, Xizhen
    CLINICAL CARDIOLOGY, 2020, 43 (03) : 235 - 241
  • [26] Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions
    Galli, Mattia
    Capodanno, Davide
    Andreotti, Felicita
    Crea, Filippo
    Angiolillo, Dominick J.
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (01) : 9 - 21
  • [27] Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following Percutaneous Coronary Intervention
    Yerasi, Charan
    Case, Brian C.
    Forrestal, Brian J.
    Torguson, Rebecca
    Weintraub, William S.
    Garcia-Garcia, Hector M.
    Waksman, Ron
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 135 : 154 - 165
  • [28] Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy
    Ho, Ming-Yun
    Chen, Po-Wei
    Feng, Wen-Han
    Su, Chun-Hung
    Huang, Sheng-Wei
    Cheng, Chung-Wei
    Yeh, Hung-I
    Chen, Ching-Pei
    Huang, Wei-Chun
    Fang, Ching-Chang
    Lin, Hui-Wen
    Lin, Sheng-Hsiang
    Hsieh, I-Chang
    Li, Yi-Heng
    PLOS ONE, 2021, 16 (05):
  • [29] Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy
    Chen, P. -W.
    Ho, M. -Y.
    Feng, W. -H.
    Su, C. -H.
    Huang, S. -W.
    Cheng, C. -W.
    Yeh, H. -I.
    Chen, C. -P.
    Huang, W. -C.
    Fang, C. -C.
    Lin, H. -W.
    Lin, S. -H.
    Hsieh, I. -C.
    Li, Y. -H.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1208 - 1208
  • [30] In CAD, P2Y12 inhibitor vs. aspirin monotherapy reduces a composite CV outcome without increasing major bleeding
    Tannu, Manasi
    Newby, L. Kristin
    ANNALS OF INTERNAL MEDICINE, 2023, 176 (11) : JC123 - JC123
12345